Exor at €72 is a rare “capital-structure arbitrage”: the market prices the whole holding company below its Ferrari stake, handing investors the rest of the portfolio for free—if they can stomach the cycle and complexity.
Overview
Exor enters 2026 with an unusually large gap between market price (€72.45) and intrinsic value, with NAV estimated around €175–€180 per share—implying a ~58–60% discount, far wider than its historical 30–40% range. The market’s pessimism is driven by cyclical headwinds at Stellantis (North America inventory correction, margin compression, product cadence issues) and CNH (ag-cycle trough), and by skepticism toward complex holding-company structures. However, Exor’s fundamentals remain strong: a “pristine” balance sheet with ~5.5% LTV, meaningful liquidity (~€1.5bn cash), and a portfolio anchored by Ferrari—whose gross value alone (~€18.3bn) exceeds Exor’s entire market cap (~€15.4bn). That dynamic implies the market is assigning a negative value to Exor’s other assets (Stellantis, CNH, Philips, Lingotto, Ventures, cash). CEO John Elkann’s strategic pivot is gradually reducing industrial cyclicality and increasing exposure to healthcare and investment/technology via a 17.5% Philips stake, Lingotto’s $9.8bn AUM platform, and Ventures. Shareholder returns are actively supported through a €1bn 2025 buyback executed at deep discounts, mechanically accreting NAV per share. The re-rating roadmap depends on Stellantis stabilization, Philips margin expansion post-settlement, and continued buyback-driven compounding, with macro risks (tariffs, trade fragmentation) acknowledged but partially offset by the margin of safety in valuation.